JAZZ saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 09, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on November 27, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on JAZZ as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
JAZZ moved below its 50-day moving average on November 08, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for JAZZ entered a downward trend on November 21, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JAZZ's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .
JAZZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JAZZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.121) is normal, around the industry mean (20.498). P/E Ratio (140.845) is within average values for comparable stocks, (137.283). JAZZ's Projected Growth (PEG Ratio) (85.758) is very high in comparison to the industry average of (7.811). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (2.157) is also within normal values, averaging (329.636).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAZZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products
|ETFs / NAME||Price $||Chg $||Chg %|
|SoFi Social 50 ETF|
|Blackrock Muniyield Quality Fund III|
|VictoryShares Core Plus Intmdt Bond ETF|
|Technology Select Sector SPDR® ETF|
|BNY Mellon Concentrated Internatnl ETF|
A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with AMLX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then AMLX could also see price increases.